Immune checkpoint inhibitors (ICIs), such as antibodies against CTLA-4, PD-1, and its ligand PD-L1, can restore immune cell activation, which aids anticancer immune responses for cancer immunotherapy [197,198]. Here, CD274 is linked to cancer.